

Dexamethasone/etoposide

S

Lack of efficacy: case report

A 5-month-old girl experienced a lack of efficacy during treatment with dexamethasone and etoposide for haemophagocytic lymphohistiocytosis (HLH).

The girl was hospitalised due to sudden-onset jaundice and acute liver failure. Following multiple analyses, she started receiving meropenem, vancomycin, glucose [dextrose] water and several unspecified inotropic agents. Since her clinical condition deteriorated, she was admitted to the paediatric ICU, where she was intubated. Thereafter, she tested positive for SARS-CoV-2. Further analyses confirmed rapid progression of sudden-onset jaundice to HLH, possibly associated with COVID-19 infection. Hence, she started receiving dexamethasone and etoposide [*routes and dosages not stated*]. However, in spite of medical therapy and supportive care, she passed away due to HLH, after 2 days of ICU admission.

Ataollahi M, et al. Consider Hemophagocytic Lymphohistiocytosis as a New Cause of Death in COVID-19 with Presentation of Acute Liver Failure: A Case Report. *Pediatric Infectious Disease Journal* 41: E186, No. 4, Apr 2022. Available from: URL: <http://journals.lww.com/pidj> 803659591